Haemonetics Corporation
HAE
$53.12
-$0.62-1.15%
NYSE
| 06/28/2025 | 03/29/2025 | 12/28/2024 | 09/28/2024 | 06/29/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.35B | 1.36B | 1.37B | 1.36B | 1.33B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.35B | 1.36B | 1.37B | 1.36B | 1.33B |
| Cost of Revenue | 563.91M | 591.26M | 614.16M | 616.86M | 610.16M |
| Gross Profit | 782.14M | 769.57M | 759.35M | 744.37M | 723.73M |
| SG&A Expenses | 427.10M | 428.53M | 426.96M | 427.33M | 430.67M |
| Depreciation & Amortization | 47.18M | 48.26M | 47.39M | 42.07M | 37.03M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.10B | 1.13B | 1.15B | 1.14B | 1.13B |
| Operating Income | 245.60M | 231.64M | 224.18M | 217.06M | 201.99M |
| Income Before Tax | 210.53M | 212.07M | 164.75M | 158.86M | 146.99M |
| Income Tax Expenses | 47.19M | 44.39M | 34.68M | 35.05M | 32.10M |
| Earnings from Continuing Operations | 163.34 | 167.68 | 130.07 | 123.81 | 114.89 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 163.34M | 167.68M | 130.07M | 123.81M | 114.89M |
| EBIT | 245.60M | 231.64M | 224.18M | 217.06M | 201.99M |
| EBITDA | 354.11M | 340.53M | 330.60M | 317.99M | 296.85M |
| EPS Basic | 3.30 | 3.34 | 2.56 | 2.43 | 2.26 |
| Normalized Basic EPS | 2.62 | 2.60 | 2.57 | 2.56 | 2.44 |
| EPS Diluted | 3.28 | 3.32 | 2.54 | 2.41 | 2.23 |
| Normalized Diluted EPS | 2.60 | 2.58 | 2.55 | 2.53 | 2.40 |
| Average Basic Shares Outstanding | 198.49M | 201.32M | 202.91M | 203.40M | 203.23M |
| Average Diluted Shares Outstanding | 199.71M | 202.92M | 204.85M | 205.66M | 205.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |